Hva Skjer’a ?
Denne tråden er stengt for nye innlegg.
01.10.2021 kl 16:07
225000 aksjer omsatt før 09:10 på stigende priser på en «negativ børsdag»....
Her er det definitivt noe som skjer - stay tuned...
Her er det definitivt noe som skjer - stay tuned...
Redigert 15.09.2021 kl 17:36
Du må logge inn for å svare
Hildebart
05.03.2021 kl 15:29
8802
Ja, da blir det spennende om det kommer noe med krutt i til helga. Men først får vi se om det blir litt trangt i døra før den stenger for dagen? Holder seg bedre enn tidligere nå synes jeg. Ender vi over 31?
klaesp
05.03.2021 kl 18:24
8392
he ACCORD-2 clinical trial
ACCORD-2 is a new UK national multi-centre randomised Phase 2 clinical trial initiative which will rapidly investigate bemcentinib’s efficacy and safety for the treatment of COVID-19 in hospitalised UK NHS patients.
Funded by the UK Department of Health and Social Care and UK Research and Innovation, the study will rapidly commence testing in 120 subjects – 60 hospitalised COVID-19 patients and 60 control group - across 6 UK NHS hospital trusts. It is anticipated that the top line data will readout within a few months and it will be open source and freely available to enable global knowledge sharing and collaboration. Based on the data, the study may progress to Phase III testing and to rapid marketing approval.
Why was bemcentinib chosen?
COVID-19 is a respiratory disease caused by the coronavirus SARS-CoV-2. There are currently no approved medical treatments or vaccines for COVID-19 but preclinical data suggests that bemcentinib is potentially useful for the treatment of early SARS-CoV-2 infection.
Bemcentinib selectively inhibits AXL kinase activity, blocking viral entry and enhancing the anti-viral type I interferon response, a key cellular defence mechanism against viral infection.
It has previously demonstrated a key role in cancer treatment: preventing immune evasion, drug resistance and metastasis in a variety of cancer trials and it has been reported to exhibit potent anti-viral activity in preclinical models against several enveloped viruses, including Ebola and Zika virus. The drug has to date been shown to be safe and well-tolerated in hundreds of patients and in many cases taken daily for several years.
BerGenBio CEO Richard Godfrey commented: “We are delighted to be part of this initiative which is a ground-breaking partnership between government, academia and industry. We are hopeful that bemcentinib can play a significant role in the global effort to find suitable treatment options for COVID-19 patients, which has had such serious implications for so many people and thereby ease pressures on hospital intensive care units, and ultimately treat thousands of patients. We are poised to commence dosing in the coming days and will provide results as soon as is practically possible.”
Mewburn Ellis Partner Rob Andrews said: “Over the years we have seen first-hand that BerGenBio is a highly innovative company able to forge productive strategic partnerships. This status is underlined by BGB’s participation in the first wave of the ACCORD-2 study, an exciting and inspirational new project that we are proud to support in these challenging times.”
BerGenBio are a clinical stage biopharmaceutical company who we are proud to have worked with for nearly 10 years. Based in Norway, the company focuses on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.
You can read the full press release here. https://www.mewburn.com/news-insights/bergenbios-bemcentinib-selected-for-fast-track-as-potential-treatment-for-coronavirus-covid-19
ACCORD-2 is a new UK national multi-centre randomised Phase 2 clinical trial initiative which will rapidly investigate bemcentinib’s efficacy and safety for the treatment of COVID-19 in hospitalised UK NHS patients.
Funded by the UK Department of Health and Social Care and UK Research and Innovation, the study will rapidly commence testing in 120 subjects – 60 hospitalised COVID-19 patients and 60 control group - across 6 UK NHS hospital trusts. It is anticipated that the top line data will readout within a few months and it will be open source and freely available to enable global knowledge sharing and collaboration. Based on the data, the study may progress to Phase III testing and to rapid marketing approval.
Why was bemcentinib chosen?
COVID-19 is a respiratory disease caused by the coronavirus SARS-CoV-2. There are currently no approved medical treatments or vaccines for COVID-19 but preclinical data suggests that bemcentinib is potentially useful for the treatment of early SARS-CoV-2 infection.
Bemcentinib selectively inhibits AXL kinase activity, blocking viral entry and enhancing the anti-viral type I interferon response, a key cellular defence mechanism against viral infection.
It has previously demonstrated a key role in cancer treatment: preventing immune evasion, drug resistance and metastasis in a variety of cancer trials and it has been reported to exhibit potent anti-viral activity in preclinical models against several enveloped viruses, including Ebola and Zika virus. The drug has to date been shown to be safe and well-tolerated in hundreds of patients and in many cases taken daily for several years.
BerGenBio CEO Richard Godfrey commented: “We are delighted to be part of this initiative which is a ground-breaking partnership between government, academia and industry. We are hopeful that bemcentinib can play a significant role in the global effort to find suitable treatment options for COVID-19 patients, which has had such serious implications for so many people and thereby ease pressures on hospital intensive care units, and ultimately treat thousands of patients. We are poised to commence dosing in the coming days and will provide results as soon as is practically possible.”
Mewburn Ellis Partner Rob Andrews said: “Over the years we have seen first-hand that BerGenBio is a highly innovative company able to forge productive strategic partnerships. This status is underlined by BGB’s participation in the first wave of the ACCORD-2 study, an exciting and inspirational new project that we are proud to support in these challenging times.”
BerGenBio are a clinical stage biopharmaceutical company who we are proud to have worked with for nearly 10 years. Based in Norway, the company focuses on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.
You can read the full press release here. https://www.mewburn.com/news-insights/bergenbios-bemcentinib-selected-for-fast-track-as-potential-treatment-for-coronavirus-covid-19
klaesp
05.03.2021 kl 18:29
8381
Denne liker jeg
bemcentinib produced by BerGenBio has been selected as a first candidate in a first wave of new and existing medicines to be tested through the Accelerating COVID-19 Research & Development: Phase 2 platform (ACCORD-2) study.
Mener jeg har lest et sted at Bergenbio er med på å sponse studien (accord 2) med et mindre beløp.. kan det stemme?
bemcentinib produced by BerGenBio has been selected as a first candidate in a first wave of new and existing medicines to be tested through the Accelerating COVID-19 Research & Development: Phase 2 platform (ACCORD-2) study.
Mener jeg har lest et sted at Bergenbio er med på å sponse studien (accord 2) med et mindre beløp.. kan det stemme?
Redigert 05.03.2021 kl 18:42
Du må logge inn for å svare
klaesp
05.03.2021 kl 19:02
8363
Three potential drugs are currently in the study:
MEDI3506 – an IL-33 monoclonal antibody
Zilucoplan – a complement C5 inhibitor that could block severe inflammatory responses, such as a ‘cytokine storm’, in COVID-19 patients
Bemcentinib – AXL inhibitor with early data showing it can reduce viral infection and lung inflammation and blocks the SARS-CoV-2 coating from interacting and gaining entry into cells
Treatments showing promise will be fed into the large-scale UK COVID-19 trials, such as RECOVERY Plus, currently the world’s largest clinical trial for COVID-19 treatment.
MEDI3506 – an IL-33 monoclonal antibody
Zilucoplan – a complement C5 inhibitor that could block severe inflammatory responses, such as a ‘cytokine storm’, in COVID-19 patients
Bemcentinib – AXL inhibitor with early data showing it can reduce viral infection and lung inflammation and blocks the SARS-CoV-2 coating from interacting and gaining entry into cells
Treatments showing promise will be fed into the large-scale UK COVID-19 trials, such as RECOVERY Plus, currently the world’s largest clinical trial for COVID-19 treatment.
JanH
05.03.2021 kl 19:59
8284
Når kom disse nyhetene? Er dette nyheter som allerede er inkludert i dagens kurs? Eller vil dette påvirke (positivt) kursen på mandag?
Nanoq
05.03.2021 kl 21:26
8088
Den svake og skuffende utviklingen i BGBIO de siste ukene skyldes nok mest at US biotech sektoren er ned med ca. 20% den siste måneden (jfr. div. US biotechfond/index). Og ikke lavere tillit til selskapet.
For oss som er investert i BGBIO handler det etter min mening om å være tålmodig og avvente Bemcentinib-nyheter omkring kreft og Covid-19. Jeg mener at vi har mye positivt i vente her.
For oss som er investert i BGBIO handler det etter min mening om å være tålmodig og avvente Bemcentinib-nyheter omkring kreft og Covid-19. Jeg mener at vi har mye positivt i vente her.
Redigert 05.03.2021 kl 21:27
Du må logge inn for å svare
Yzf R1
05.03.2021 kl 23:20
8045
Kondolerer så mye Nanoq,tris det også rammer så unge mennesker..
Husk å donere noen kr til dette formål som i år foregår ved vips.
Husk å donere noen kr til dette formål som i år foregår ved vips.
Rule
06.03.2021 kl 09:11
7759
Ny dag ny topic. Kursen er stærk og det ser ud til vi snur opad. Februar:
BGBIO: -13%
Genmab: -24%
Hansa biopharma: -18%
Plus vi har set danske Genmab trække deres AXL hæmmer kandidat af banen. De havde en anden teknologi end BGBIO, som havde for høj toxicitet.
Genmab tjener styrtende med penge på deres cancer middel Darcalax og BGBIO er en oplagt opkøbs kandidat for dem. Det vil kunne bringe den helt store bonus på lang sigt med et område der har en kjæmpe fremtid ind i en samlet portefolio.
BGBIO: -13%
Genmab: -24%
Hansa biopharma: -18%
Plus vi har set danske Genmab trække deres AXL hæmmer kandidat af banen. De havde en anden teknologi end BGBIO, som havde for høj toxicitet.
Genmab tjener styrtende med penge på deres cancer middel Darcalax og BGBIO er en oplagt opkøbs kandidat for dem. Det vil kunne bringe den helt store bonus på lang sigt med et område der har en kjæmpe fremtid ind i en samlet portefolio.
Rule
06.03.2021 kl 09:13
7794
Sorry - jeg kiggede 1 måned bagud og så endnu bedre:
BGBIO: -6%
Genmab: -24%
Hansa biopharma: -18%
--------------------------
realtivt resultat: BGBIO = +12% - 18%
BGBIO: -6%
Genmab: -24%
Hansa biopharma: -18%
--------------------------
realtivt resultat: BGBIO = +12% - 18%
Billyjojimbob
06.03.2021 kl 09:31
7750
Gullit
06.03.2021 kl 09:50
7692
Dette var så bra att vi kliner til med hele meldingen.. ser vi en game changer!!
06.03.2021 09:27:51: BERGENBIO PRESENTS PRECLINICAL COVID-19 DATA AT ANNUAL CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2021)
Bergen, Norway, 6 March 2021?- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, today delivered a Science Spotlight oral presentation
on preclinical COVID-19 data at the annual Conference on Retroviruses and
Opportunistic Infections (CROI), taking place from 6-10 March 2021.
The presentation was led by BerGenBio's collaborator, Professor Wendy Maury,
Professor of Microbiology and Immunology at the University of Iowa (Iowa City,
USA), who presented data showing that AXL enhances the ability of SARS-CoV-2 to
infect cell lines from the human airway, increasing the amount of virus measured
in those cells. Treating the human cell lines, Vero E6 and human ACE2-expressing
A549 lung cancer cell lines, with the AXL kinase inhibitor, bemcentinib reduces
the amount of SARS-CoV-2 virus infecting these cells, and it does this by
reducing ACE2-mediated viral cell entry by endocytosis, rather than at the cell
surface.
Additionally an in vivo study also measured the effect of bemcentinib to treat a
type of coronavirus which naturally infects mice - murine hepatitis virus (MHV).
In this study, not only was bemcentinib found to significantly inhibit the viral
load of MHV found in the liver of these animals, but it also significantly
enhanced signatures of a type I IFN response, a potent mediator of the innate
antiviral response.
In conclusion, the effect of bemcentinib demonstrated potent antiviral effects
in preclinical SARS-CoV-2 and other coronavirus models. Further, the findings
support BerGenBio's ongoing Phase II trial evaluating bemcentinib for the
treatment of hospitalised COVID-19 patients in South Africa and India.
The presentation will be made available on BerGenBio's website under
'Presentations'.
Full details of the presentation are as follows:
Title: Targeting the receptor AXL by bemcentinib prevents SARS-CoV-2 infection
Author: Professor Wendy Maury, Professor of Microbiology and Immunology at the
University of Iowa (Iowa City, USA)
Abstract No. 2672
-Ends-
06.03.2021 09:27:51: BERGENBIO PRESENTS PRECLINICAL COVID-19 DATA AT ANNUAL CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI 2021)
Bergen, Norway, 6 March 2021?- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, today delivered a Science Spotlight oral presentation
on preclinical COVID-19 data at the annual Conference on Retroviruses and
Opportunistic Infections (CROI), taking place from 6-10 March 2021.
The presentation was led by BerGenBio's collaborator, Professor Wendy Maury,
Professor of Microbiology and Immunology at the University of Iowa (Iowa City,
USA), who presented data showing that AXL enhances the ability of SARS-CoV-2 to
infect cell lines from the human airway, increasing the amount of virus measured
in those cells. Treating the human cell lines, Vero E6 and human ACE2-expressing
A549 lung cancer cell lines, with the AXL kinase inhibitor, bemcentinib reduces
the amount of SARS-CoV-2 virus infecting these cells, and it does this by
reducing ACE2-mediated viral cell entry by endocytosis, rather than at the cell
surface.
Additionally an in vivo study also measured the effect of bemcentinib to treat a
type of coronavirus which naturally infects mice - murine hepatitis virus (MHV).
In this study, not only was bemcentinib found to significantly inhibit the viral
load of MHV found in the liver of these animals, but it also significantly
enhanced signatures of a type I IFN response, a potent mediator of the innate
antiviral response.
In conclusion, the effect of bemcentinib demonstrated potent antiviral effects
in preclinical SARS-CoV-2 and other coronavirus models. Further, the findings
support BerGenBio's ongoing Phase II trial evaluating bemcentinib for the
treatment of hospitalised COVID-19 patients in South Africa and India.
The presentation will be made available on BerGenBio's website under
'Presentations'.
Full details of the presentation are as follows:
Title: Targeting the receptor AXL by bemcentinib prevents SARS-CoV-2 infection
Author: Professor Wendy Maury, Professor of Microbiology and Immunology at the
University of Iowa (Iowa City, USA)
Abstract No. 2672
-Ends-
klaesp
06.03.2021 kl 10:05
7582
Likte best denne:)
In conclusion, the effect of bemcentinib demonstrated potent antiviral effects
in preclinical SARS-CoV-2 and other coronavirus models. Further, the findings
support BerGenBio's ongoing Phase II trial evaluating bemcentinib for the
treatment of hospitalised COVID-19 patients in South Africa and India.
In conclusion, the effect of bemcentinib demonstrated potent antiviral effects
in preclinical SARS-CoV-2 and other coronavirus models. Further, the findings
support BerGenBio's ongoing Phase II trial evaluating bemcentinib for the
treatment of hospitalised COVID-19 patients in South Africa and India.
JanH
06.03.2021 kl 10:09
7593
Bru skrev Denne meldingen ser meget bra ut.
Ja, vi får en fin utvikling på mandag. Denne kommer lett til å passere 32! Endelig en melding som virkelig er stor!
ctrlaltdel
06.03.2021 kl 10:46
7511
Tør nesten ikke håpe på noe når det gjelder BGBIO men nå har aksjen BGBIO bygd opp et enormt potensial som vil føre til en spike takeoff. Kan ikke forstå annet enn atfor eksisterende eiere så starter reisen nå.
BioBull
06.03.2021 kl 11:01
7415
https://www.bergenbio.com/investors/presentations/
Se under :
Scientific Presentations
2021
CROI 2021, Wendy Maury et al.
6 March 2021
Targeting of the Receptor Tyrosine Kinase AXL by Bemcentinib prevents SARS-CoV-2 infection
Se under :
Scientific Presentations
2021
CROI 2021, Wendy Maury et al.
6 March 2021
Targeting of the Receptor Tyrosine Kinase AXL by Bemcentinib prevents SARS-CoV-2 infection
Nattergalen
06.03.2021 kl 12:57
7194
Yngling ØH skrev Kondolerer! Tøft av deg å dele!
Jeg leser dine og Bio-Bulls innlegg med stor glede!!! Hva er det som mangler før studiene går over i fase3?
MiniMe
06.03.2021 kl 13:01
7306
OceanQ skrev Er det noen forskjell på dagens TO børsmeldinger?
Ja!
The effect of bemcentinib was found to prevent infection by SARS-CoV-2, as assessed by viral transcripts in RNAseq studies, as well as reduce the viral load by qRT-PCR analysis in human lung epithelial, A549-hACE2 and Vero E6 cell-line models. Bemcentinib was reported to reduce virus internalization, without affecting virus binding, by limiting the endosomal entry route to the host cells. In vivo, bemcentinib was found to significantly reduce murine-hepatitis-virus liver titers, which is a measure of virus load, and significantly enhanced signatures of type I IFN response.”
The effect of bemcentinib was found to prevent infection by SARS-CoV-2, as assessed by viral transcripts in RNAseq studies, as well as reduce the viral load by qRT-PCR analysis in human lung epithelial, A549-hACE2 and Vero E6 cell-line models. Bemcentinib was reported to reduce virus internalization, without affecting virus binding, by limiting the endosomal entry route to the host cells. In vivo, bemcentinib was found to significantly reduce murine-hepatitis-virus liver titers, which is a measure of virus load, and significantly enhanced signatures of type I IFN response.”
For meg fremstår dette som et klart og tydlig kjøpssignal. Alt tyder nå på at bemcentinib kan brukes aktivt i kampen mot Covid og dets mutasjoner. Når vi i tillegg har sett at virus load er en klar indikator på hvor syk man blir, så blir dette bare enda mer tydelig. Om bemcentinib er såpass effektivt at legen kan skrive ut en resept til smittede og dette omtrent garanterer for at sykdommen ikke blir alvorlig kan man i utgangspunktet åpne hele samfunnet uten at man trenger noen form for vaksinering (vel, forrutenom kanskje rent proaktivt for risikogrupper). Det er altså en game changer.
focuss
06.03.2021 kl 13:24
7176
Det er bare ett preklinisk studie som er referert til mange ganger tidligere.
King
06.03.2021 kl 13:28
7140
Ja det er mest sannsynlig en gamechanger. Mulig strafferunde som G kaller det men deretter salg av Bemcentinib for behandling av C-19 andre halvår 2021. Faktisk et svært realistisk scenario.
MiniMe
06.03.2021 kl 13:42
7062
Helt enig. Her vil nok nødparagrafen slå inn parallellt med større studie. Gjerne WHO solidarity clinical trail.
Vi er nok nærmere enn noen her skisserer. Men det er lov å tenke selv. Samtidig er vi fortsatt med i Accord og neste steg derfra kan vær Recovery da det stadig detter ut medisiner som er med der, nå nylig Colchicone.
Vi er nok nærmere enn noen her skisserer. Men det er lov å tenke selv. Samtidig er vi fortsatt med i Accord og neste steg derfra kan vær Recovery da det stadig detter ut medisiner som er med der, nå nylig Colchicone.
ctrlaltdel
06.03.2021 kl 13:43
7213
the findings support BerGenBio's ongoing Phase II trial evaluating bemcentinib for the treatment of hospitalised COVID-19 patients in South Africa and India.
Trenger du å oversette så prøv google translate
Trenger du å oversette så prøv google translate
Skulle ikke forundre meg om det kommer bud på hele sulamitten om ikke så lenge.
Bru
06.03.2021 kl 14:23
9445
Billyjojimbob skrev Nå skal det luktes på 40 lappen igjen👍
Mye som tyder på det ja😀Blir spennende. Har Focuss solgt ut alle aksjene sine 😂😂😂😂😂
Redigert 06.03.2021 kl 14:25
Du må logge inn for å svare
Start
06.03.2021 kl 15:36
9151
Billyjojimbob skrev Nå skal det luktes på 40 lappen igjen👍
Blir vel som vanlig 2kr opp så ned igjen.men det er lov å håpe.det er vel slik det har blitt desverre.nesten uansett hva de melder.så hadde vært hyggelig med en overraskelse her i gården.
klaesp
06.03.2021 kl 15:58
9094
Jepp, det kan bli en avgjørende faktor hvor Bemcentintinib er i pille form og kan tas tildlig i sykdomsforløpet , behov for innkeggelse på sykehus kan reduseres betydelig Vs andre medikamenter som må tas intravenøs på sykehus..
Redigert 06.03.2021 kl 16:02
Du må logge inn for å svare
sry
06.03.2021 kl 16:37
8942
Vet at det er lørdag, men dette er jo en nyhet som flere medier burde skrevet om. Ikke noe på E24, FA, VG etc.
Hayen
06.03.2021 kl 16:39
8906
Slettet brukerskrev Skulle ikke forundre meg om det kommer bud på hele sulamitten om ikke så lenge.
Mohn stopper alle mulige forsøk på å kjøpe selskapet for småpenger
Hildebart
06.03.2021 kl 16:55
8822
focuss
06.03.2021 kl 16:56
8792
Ctraltdel.
Har ingen problem med engelsken. De sier at resultatene gir støtte til studiene. Med andre ord gir basis for å starte studiene. Nå er det jo ikke noe nytt at de skriver børsmeldinger som kan misforstås. Kun prekliniske data. Ingen kliniske data er presentert
Har ingen problem med engelsken. De sier at resultatene gir støtte til studiene. Med andre ord gir basis for å starte studiene. Nå er det jo ikke noe nytt at de skriver børsmeldinger som kan misforstås. Kun prekliniske data. Ingen kliniske data er presentert
Hayen
06.03.2021 kl 17:18
8711
"Godfrey er klar på at medikamentet kan bli en «game changer» i kampen mot koronaviruset."
focuss
06.03.2021 kl 18:38
8525
Carrera
At du ikke klarer skrive nicket mitt riktig er nok ingen misforståelse, bare en del av den normale sjikane sjargongen på denne tråden. En oppførsel moderator ikke setter pris på. Men er man uten argumenter så er det vel lett å ty til slikt. Dersom du klarer å forstå meldingen til å omhandle kliniske resultater så skal det ikke mye til før du misforstår.
At du ikke klarer skrive nicket mitt riktig er nok ingen misforståelse, bare en del av den normale sjikane sjargongen på denne tråden. En oppførsel moderator ikke setter pris på. Men er man uten argumenter så er det vel lett å ty til slikt. Dersom du klarer å forstå meldingen til å omhandle kliniske resultater så skal det ikke mye til før du misforstår.
Bearwizard
06.03.2021 kl 18:49
8458
Synes ikke du skal sette deg på din høye hest når det gjelder å karakterisere andre...jeg regner med at du begynner å bli nervøs..tenk om BB lykkes..hvilken gedigen nedtur for deg
TommyHagen
06.03.2021 kl 19:02
8546
Enig, personangrep og sjikane skulle være unødvendig!
Man kan snu og vende på uttalelser og caset, så mye man måtte orke. Udiskuterbar hvorvidt dette er gode nyheter fra Wendy.
Definitivt av betydning. Bekrefter preklinisk in vivo effekt vs in vitro og teoretisk effekt i vår.
Godt er det også å se at RG er noe mindre haussende.
Kommer aksjen til å gå på dette? Neppe.
Men bunnen er nok satt foreløpig.
Man kan snu og vende på uttalelser og caset, så mye man måtte orke. Udiskuterbar hvorvidt dette er gode nyheter fra Wendy.
Definitivt av betydning. Bekrefter preklinisk in vivo effekt vs in vitro og teoretisk effekt i vår.
Godt er det også å se at RG er noe mindre haussende.
Kommer aksjen til å gå på dette? Neppe.
Men bunnen er nok satt foreløpig.